dr. craig a. lewis - fda overview of antibiotic regulatory activities (guidance 213, vfd, antibiotic...
DESCRIPTION
FDA Overview of Antibiotic Regulatory Activities (Guidance 213, VFD, antibiotic use data collection) - Craig A. Lewis, DVM MPH DACVPM, U.S. Food and Drug Administration, from the 2014 NIAA Annual Conference titled 'The Precautionary Principle: How Agriculture Will Thrive', March 31 - April 2, 2014, Omaha, NE, USA. More presentations at http://www.trufflemedia.com/agmedia/conference/2014_niaa_how_animal_agriculture_will_thriveTRANSCRIPT
FDA Overview of
Antibiotic Regulatory Activities
Craig A. Lewis, DVM, MPH, DACVPM
Center for Veterinary Medicine (CVM)
U.S. Food and Drug Administration (FDA)
Presented to
NIAA 2014 Annual Conference
Antibiotics CouncilApril 1, 2014 1
Background
FDA’s ongoing strategy
Guidance for industry (GFI) #209
Draft guidance for industry (GFI) #213
Veterinary Feed Directives
Next Steps
Finalizing VFD Rule
Monitoring Progress
Topics
Antimicrobial Resistance – In Perspective
Complex, multi-factorial issue
Acquired vs. naturally occurring
Use as a driver of resistance
All uses (human, animal, horticultural, other) are part of the picture
Gaps in our understanding of the issue remain – the
science continues to evolve.
But, these complexities and uncertainties do not mean
that steps can’t be identified to mitigate risk.
Antibiotic Use in Animal Agriculture
Has been the subject of scientific and policy
debate for decades.
Consumers, public health advocates, Congress,
and others continue to be concerned about public
health impacts.
While debate continues, identify measures that
address public health concern and that continue to
assure animal health needs are met.
Remaining Concerns
A process is in place, with implementation of GFI 152 in
2003, that now evaluates the safety of antimicrobial new
animal drugs with regard to their microbiological effects on
bacteria of human health concern.
However, concerns remain about products that pre-date
current assessment process.
Focus of recent efforts is on taking steps to assure that
existing antibiotics (including those that predate 2003
assessment process) are used as judiciously as possible.
Judicious Use of Antimicrobials
Guidance 209 – ‘‘The Judicious Use of
Medically Important Antimicrobial Drugs in
Food-Producing Animals’’
Published as draft in June 2010
Finalized April 2012
Describes overall policy direction
6
Judicious Use: Guidance 209
Focus is on initiating steps to assure that medically important antimicrobial drugs are used as judiciously as possible.
Antimicrobials must continue to be available to combat disease in animals,
including treatment, control, and prevention.
Goal: preserve availability of effective drugs (for both humans and animals).
7
Judicious Use: Guidance 209
Two key principles outlined in Guidance 209:
1. Limit use of medically important antimicrobial
drugs to those uses considered necessary for
assuring animal health (i.e., therapeutic
purposes).
2. Increase veterinary involvement/consultation.
8
Published December 2013
Provides more detailed guidance on
implementation of key principles in Guidance 209
Definition of “medically important”
Process for updating product labels
Data required to obtain approval of new uses
Proposed implementation timeline
Guidance 213: Overview
9
Guidance 213: Medical Importance
Proposed definition of medically important: those
drugs currently listed in GFI #152, Appendix A
regardless of their ranking
GFI #152 provides guidance on evaluating the potential
effects of antimicrobial new animal drugs on non-target
bacteria as part of the new animal drug application
process.
Appendix A describes a process for ranking
antimicrobial drugs with regard to their relative
importance in human medicine.
10
Guidance 213: Affected Drugs
Medically important antimicrobials
Administered in feed/water
Approved for production uses
Available OTC
11
Guidance 213: Affected Drugs
7 Classes (with some examples):
Aminoglycosides (streptomycin, spectinomycin)
Lincosamides (lincomycin)
Macrolides (tylosin, erythromycin)
Penicillins (penicillin G procaine)
Streptogramins (virginiamycin)
Sulfonamides (sulfamethazine)
Tetracyclines (chlortetracycline, oxytetracycline)
12
Guidance 213: New Uses
Potential new therapeutic uses
Therapeutic = treatment, control, prevention
Includes data required to obtain approval of new uses
Any new uses are expected to:
demonstrate therapeutic effectiveness
have defined dosing duration
include veterinary oversight
13
Guidance 213: Timeline (3 months)
Requested notification from drug sponsors as to their
intentions within 3 months (by March 12, 2014)
FDA has received responses from all of the sponsors
affected by this guidance and is very encouraged by the
positive response.
The number of affected sponsors is 26.
25 sponsors confirmed their intent to engage in Guidance #213.
These 25 sponsors hold 99.6 percent of the applications affected
by Guidance #213.
These applications represent 99.95 percent of the total sales of
products affected by Guidance #213, based on 2011 data.14
Guidance 213: Timeline (3 years)
Target for implementing changes to use conditions of
affected products within 3 years (by December 12, 2016)
FDA is confident that these changes can be completed within the
three-year implementation period.
Veterinary Feed Directive (VFD) streamlining
To facilitate transition to increased veterinary oversight of
medicated feeds, FDA is also updating the VFD regulation.
Intent is to implement revised VFD regulation within 3-year
timeframe, but will adjust timeframe as necessary if VFD changes
not yet in effect.
15
Veterinary Oversight
One of two key principles described in
Guidance 209:
1. Limit use of medically important antimicrobial
drugs to those uses considered necessary for
assuring animal health (i.e., therapeutic
purposes).
2. Increase veterinary involvement/consultation.
16
Veterinary Oversight
Primary objective is to include veterinarian
in decision-making process…
Does not require direct veterinarian involvement
in drug administration.
Practically, this means changing marketing
status from OTC to Rx or VFD.
17
Veterinary Feed Directive
Existing framework for veterinary oversight of feed
use drugs is the veterinary feed directive (VFD).
In 1996 Congress passed Federal Law stating that
medicated feeds which require veterinary
oversight are designated VFDs.
In 2001 FDA finalized regulations for distribution
and use of VFDs.
18
Updating the VFD Process
Changes intended to make process more
efficient
Critically evaluated all current requirements
Information required on VFD form
Transmitting VFD
Recordkeeping requirements
Specificity of order 19
Proposed VFD Rule: Major Provisions
Replace the explicit “veterinarian-client-patient relationship”
(VCPR) provision with the requirement that veterinarians
ordering the use of VFD drugs must do so “in compliance
with all applicable veterinary licensing and practice
requirements”
Revise the definition of Category II to eliminate the
automatic classification of VFD drugs into Category II.
Reduce the recording keeping burden for VFD drugs from
2 years to 1 year.
20
Proposed VFD Rule: Example
Current process
Requires VFD orders be written for a specific amount of
medicated feed for specifically identified animals.
Proposed change
Allows veterinarians to be this specific, but also
provides the flexibility for veterinarians to issue a
broader "standing order"
For up to 6 months
Limited by approximate number of animals specified on the
VFD
21
Guidance #213: Next Steps
Finalize VFD rule
Proposed rule published with final GFI #213
90-day public comment period (closed 3-12-2014)
Monitoring Progress of Guidance #213
Notifying Public
Assessing Impacts
22
Notifying the Public of Progress
Listing all antimicrobial products and sponsors affected by
GFI #213
Publishing summary indicating the level of engagement of
affected drug sponsors following the 3-month notification
period indicated in the guidance
Notifying the public of completed changes to affected
products through publication of approval of supplemental
new animal drug applications
Evaluating the rate of adoption of the recommended
changes at the end of 3 years
23
Assessing Impacts of Strategy
Monitoring trends in antimicrobial resistance among
foodborne bacteria from humans, retail meats, and animals
through the NARMS program.
Enhancing data FDA currently collects on the sales and
distribution of antimicrobial drugs intended for use in food-
producing animals.
Collaborating with other agencies, including USDA and the
CDC, to explore approaches for enhancing current data
collection efforts in order to measure the effectiveness of
the strategy.
24
A Collaborative Approach
FDA believes that a collaborative approach is the
fastest way to implement the changes outlined in
Guidance #213.
We have worked with stakeholders, including
animal pharmaceutical companies, to encourage
their cooperation on this important public health
issue, and we are confident in their support.
25
The Role of Animal Producers and
Veterinarians
Once drug companies voluntarily make these changes,
animal producers and veterinarians can no longer use
these products for production purposes, and therapeutic
use of these products would require veterinary oversight.
By law, drugs administered through feed must be used
according to the approved labeling.
In addition, the extralabel use of approved drugs in animals
by or on the lawful order of licensed veterinarians is limited
to situations where the health of an animal is threatened or
suffering or death may result from failure to treat.
26
Judicious Prevention Use
A veterinarian practicing judicious use principles would
consider relevant factors to determine:
the risk of a specific bacterial disease,
whether it would be appropriate in a particular situation to use
medically important antimicrobials for prevention purposes.
For example, the veterinarian would consider:
the way the drug acts against the particular bacteria in question,
whether it can effectively reach the site of infection,
how long the drug maintains effective levels at the site of infection.
27
Judicious Prevention Use
Other important factors veterinarians consider
when determining whether a particular drug is
appropriate for preventive use include whether:
1. There is evidence that the drug will be effective in treating the
particular disease.
2. Such preventive use is consistent with accepted veterinary
practice.
3. The use is intended to address particular bacteria.
4. The use is appropriately targeted to animals at risk of developing a
specific disease.
5. There are no reasonable alternatives for intervention. 28
Related CVM Websites
Judicious Use of Antimicrobials:
http://www.fda.gov/AnimalVeterinary/SafetyHealth/AntimicrobialResistance
/JudiciousUseofAntimicrobials/default.htm
NARMS
http://www.fda.gov/AnimalVeterinary/SafetyHealth/AntimicrobialResistance
/NationalAntimicrobialResistanceMonitoringSystem/default.htm
ADUFA 105 Reports:
http://www.fda.gov/ForIndustry/UserFees/AnimalDrugUserFeeActADUFA/u
cm042896.htm
29
Thank You
30